Recent Advances in Nanotherapeutics for Neurological Disorders

Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side- effects, and immune responses in neurodegenerative diseases is essential for developing better therapies. The immune activation in a diseased state...

Full description

Saved in:
Bibliographic Details
Published inACS applied bio materials Vol. 6; no. 7; pp. 2614 - 2621
Main Authors Vashist, Arti, Manickam, Pandiaraj, Raymond, Andrea D., Arias, Adriana Yndart, Kolishetti, Nagesh, Vashist, Atul, Arias, Emanuel, Nair, Madhavan
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 17.07.2023
Subjects
Drug Delivery Systems
Humans
Nanotechnology - methods
Neurodegenerative Diseases - drug therapy
Pharmaceutical Preparations
Review
Nanotherapeutics
Nanomaterials
Nanotechnology
Neurological disorders
Immune interactions
Online AccessGet full text

Cover

Abstract Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side- effects, and immune responses in neurodegenerative diseases is essential for developing better therapies. The immune activation in a diseased state has complex treatment protocols and results in hurdles for clinical translation. There is an immense need for the development of multifunctional nanotherapeutics with various properties to address the different limitations and immune interactions exhibited by the existing therapeutics. Nanotechnology has proven its potential to improve therapeutic delivery and enhance efficacy. Promising advancements have been made in developing nanotherapies that can be combined with CRISPR/Cas9 or siRNA for a targeted approach with unique potential for clinical translation. Engineering natural exosomes derived from mesenchymal stem cells (MSCs), dendritic cells (DCs), or macrophages to both deliver therapeutics and modulate the immune responses to tumors or in neurodegenerative disease (ND) can allow for targeted personalized therapeutic approaches. In the present review, we summarize and overview the recent advances in nanotherapeutics in addressing the existing treatment limitations and neuroimmune interactions for developing ND therapies and provide insights into the upcoming advancements in nanotechnology-based nanocarriers.
AbstractList Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side- effects, and immune responses in neurodegenerative diseases is essential for developing better therapies. The immune activation in a diseased state has complex treatment protocols and results in hurdles for clinical translation. There is an immense need for the development of multifunctional nanotherapeutics with various properties to address the different limitations and immune interactions exhibited by the existing therapeutics. Nanotechnology has proven its potential to improve therapeutic delivery and enhance efficacy. Promising advancements have been made in developing nanotherapies that can be combined with CRISPR/Cas9 or siRNA for a targeted approach with unique potential for clinical translation. Engineering natural exosomes derived from mesenchymal stem cells (MSCs), dendritic cells (DCs), or macrophages to both deliver therapeutics and modulate the immune responses to tumors or in neurodegenerative disease (ND) can allow for targeted personalized therapeutic approaches. In the present review, we summarize and overview the recent advances in nanotherapeutics in addressing the existing treatment limitations and neuroimmune interactions for developing ND therapies and provide insights into the upcoming advancements in nanotechnology-based nanocarriers.Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side- effects, and immune responses in neurodegenerative diseases is essential for developing better therapies. The immune activation in a diseased state has complex treatment protocols and results in hurdles for clinical translation. There is an immense need for the development of multifunctional nanotherapeutics with various properties to address the different limitations and immune interactions exhibited by the existing therapeutics. Nanotechnology has proven its potential to improve therapeutic delivery and enhance efficacy. Promising advancements have been made in developing nanotherapies that can be combined with CRISPR/Cas9 or siRNA for a targeted approach with unique potential for clinical translation. Engineering natural exosomes derived from mesenchymal stem cells (MSCs), dendritic cells (DCs), or macrophages to both deliver therapeutics and modulate the immune responses to tumors or in neurodegenerative disease (ND) can allow for targeted personalized therapeutic approaches. In the present review, we summarize and overview the recent advances in nanotherapeutics in addressing the existing treatment limitations and neuroimmune interactions for developing ND therapies and provide insights into the upcoming advancements in nanotechnology-based nanocarriers.
Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side- effects, and immune responses in neurodegenerative diseases is essential for developing better therapies. The immune activation in a diseased state has complex treatment protocols and results in hurdles for clinical translation. There is an immense need for the development of multifunctional nanotherapeutics with various properties to address the different limitations and immune interactions exhibited by the existing therapeutics. Nanotechnology has proven its potential to improve therapeutic delivery and enhance efficacy. Promising advancements have been made in developing nanotherapies that can be combined with CRISPR/Cas9 or siRNA for a targeted approach with unique potential for clinical translation. Engineering natural exosomes derived from mesenchymal stem cells (MSCs), dendritic cells (DCs), or macrophages to both deliver therapeutics and modulate the immune responses to tumors or in neurodegenerative disease (ND) can allow for targeted personalized therapeutic approaches. In the present review, we summarize and overview the recent advances in nanotherapeutics in addressing the existing treatment limitations and neuroimmune interactions for developing ND therapies and provide insights into the upcoming advancements in nanotechnology-based nanocarriers.
Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side- effects, and immune responses in neurodegenerative diseases is essential for developing better therapies. The immune activation in a diseased state has complex treatment protocols and results in hurdles for clinical translation. There is an immense need for the development of multifunctional nanotherapeutics with various properties to address the different limitations and immune interactions exhibited by the existing therapeutics. Nanotechnology has proven its potential to improve therapeutic delivery and enhance efficacy. Promising advancements have been made in developing nanotherapies that can be combined with CRISPR/Cas9 or siRNA for a targeted approach with unique potential for clinical translation. Engineering natural exosomes derived from mesenchymal stem cells (MSCs), dendritic cells (DCs), or macrophages to both deliver therapeutics and modulate the immune responses to tumors or in neurodegenerative disease (ND) can allow for targeted personalized therapeutic approaches. In the present review, we summarize and overview the recent advances in nanotherapeutics in addressing the existing treatment limitations and neuroimmune interactions for developing ND therapies and provide insights into the upcoming advancements in nanotechnology-based nanocarriers.
Author Kolishetti, Nagesh
Vashist, Atul
Manickam, Pandiaraj
Arias, Emanuel
Nair, Madhavan
Vashist, Arti
Raymond, Andrea D.
Arias, Adriana Yndart
AuthorAffiliation Department of Infection & Immunology
Academy of Scientific & Innovative Research (AcSIR)
Electrodics and Electrocatalysis Division
Institute of Neuroimmune Pharmacology, Herbert Wertheim College of Medicine
Florida International University
Department of Immunology and Nanomedicine, Herbert Wertheim College of Medicine
AuthorAffiliation_xml – name: Academy of Scientific & Innovative Research (AcSIR)
– name: Department of Immunology and Nanomedicine, Herbert Wertheim College of Medicine
– name: Florida International University
– name: Electrodics and Electrocatalysis Division
– name: Institute of Neuroimmune Pharmacology, Herbert Wertheim College of Medicine
– name: Department of Infection & Immunology
Author_xml – sequence: 1
  givenname: Arti
  orcidid: 0000-0002-7519-1863
  surname: Vashist
  fullname: Vashist, Arti
  email: avashist@fiu.edu
  organization: Florida International University
– sequence: 2
  givenname: Pandiaraj
  orcidid: 0000-0001-7441-0545
  surname: Manickam
  fullname: Manickam, Pandiaraj
  organization: Academy of Scientific & Innovative Research (AcSIR)
– sequence: 3
  givenname: Andrea D.
  surname: Raymond
  fullname: Raymond, Andrea D.
  organization: Florida International University
– sequence: 4
  givenname: Adriana Yndart
  surname: Arias
  fullname: Arias, Adriana Yndart
  organization: Florida International University
– sequence: 5
  givenname: Nagesh
  orcidid: 0000-0001-5574-673X
  surname: Kolishetti
  fullname: Kolishetti, Nagesh
  organization: Florida International University
– sequence: 6
  givenname: Atul
  orcidid: 0000-0002-2843-1166
  surname: Vashist
  fullname: Vashist, Atul
  organization: Department of Infection & Immunology
– sequence: 7
  givenname: Emanuel
  surname: Arias
  fullname: Arias, Emanuel
  organization: Florida International University
– sequence: 8
  givenname: Madhavan
  surname: Nair
  fullname: Nair, Madhavan
  email: nairm@fiu.edu
  organization: Florida International University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37368486$$D View this record in MEDLINE/PubMed
BookMark eNp1kctLxDAQxoMovq8epUcRds2zjRdl8Q2iIHoO03SqkW6yJq3gf2-WXUUFL8mQ_L5vhm-2yKoPHgnZY3TMKGdHYBPU07GwlHIlV8gmV1U5KiXnqz_qDbKb0ivNDKWC6eN1siEqUWqpy01y8oAWfV9MmnfwFlPhfHEHPvQvGGGGQ-9sKtoQizscYujCs7PQFecuhdhgTDtkrYUu4e7y3iZPlxePZ9ej2_urm7PJ7QgkL_uRVFBLlQ-ldFNzCkoDs02FdauqumIohGLM2jrXtdWNavBYWolYct20UIltcrrwnQ31FJv5yBE6M4tuCvHDBHDm9493L-Y5vBtGhZKVVNnhYOkQw9uAqTdTlyx2HXgMQzJcixyp1lRndP9ns-8uX6llYLwAbAwpRWy_EUbNfDNmsRmz3EwWyD8C63roXZgP67r_ZYcLWX43r2GIPmf8H_wJIFSi4w
CitedBy_id crossref_primary_10_1007_s12668_025_01876_9
crossref_primary_10_3390_ijms25042360
crossref_primary_10_3389_fddev_2024_1436842
crossref_primary_10_3390_pharmaceutics17030281
crossref_primary_10_1016_S1474_4422_24_00476_9
crossref_primary_10_1016_j_rechem_2024_101463
crossref_primary_10_3389_fmats_2024_1396397
crossref_primary_10_3390_biomimetics10010025
crossref_primary_10_1016_j_bbi_2024_10_007
crossref_primary_10_1039_D4FO03646H
crossref_primary_10_1016_j_dscb_2024_100162
crossref_primary_10_3390_medicina60091384
crossref_primary_10_3390_pharmaceutics15122658
crossref_primary_10_1039_D5BM00179J
crossref_primary_10_2147_IJN_S436774
crossref_primary_10_1186_s12951_024_02772_2
crossref_primary_10_3390_pharmaceutics17030352
crossref_primary_10_1016_j_ejmech_2025_117357
crossref_primary_10_1007_s12668_024_01773_7
crossref_primary_10_2147_IJN_S457393
Cites_doi 10.1016/j.heliyon.2022.e09575
10.1016/j.jconrel.2017.11.040
10.1016/j.biomaterials.2016.05.044
10.3390/cells8020154
10.1126/sciadv.aay8514
10.1016/j.biopha.2018.12.133
10.3389/fimmu.2014.00658
10.1021/acsami.2c13129
10.1096/fj.09-141754
10.1111/jphp.13132
10.1021/acsanm.2c01930
10.1002/jps.24557
10.1039/C7NR07255D
10.1016/j.biomaterials.2015.11.057
10.1021/acs.bioconjchem.9b00085
10.20517/evcna.2021.04
10.1016/j.jconrel.2018.08.035
10.3389/fimmu.2020.607945
10.1016/j.mam.2021.101046
10.1080/10717544.2021.1883158
10.1002/btm2.10160
10.1021/acs.chemrev.5b00589
10.1016/0304-3940(91)90490-K
10.1021/acs.molpharmaceut.2c00763
10.3389/fbioe.2020.00315
10.1016/S1474-4422(19)30029-8
10.1208/s12249-014-0189-5
10.1016/bs.pmbts.2019.10.002
10.1016/j.brainres.2020.146738
10.1126/science.aau6977
10.1021/acs.biomac.0c01033
10.1016/j.addr.2022.114636
10.1038/nm.2965
10.1186/1750-1326-8-2
10.1007/s13365-023-01138-y
10.2217/nnm-2018-0021
10.1016/j.ijpharm.2022.122168
10.1002/jnr.1097
10.3389/fbioe.2022.954470
10.1111/j.1365-2990.1995.tb01063.x
10.1126/scirobotics.aaz9519
10.1007/s12035-016-9851-0
10.1021/acsnano.2c08774
10.1021/acsbiomaterials.2c01329
10.7150/thno.62330
10.1016/j.jconrel.2020.01.009
10.1016/j.matdes.2022.110741
10.1021/acsami.2c14220
10.1186/s12951-022-01595-3
10.1016/S1474-4422(19)30411-9
10.1021/acs.molpharmaceut.0c00170
10.3233/JAD-200056
10.1002/advs.202003937
10.1016/j.addr.2018.08.005
ContentType Journal Article
Copyright 2023 The Authors. Published by American Chemical Society
2023 The Authors. Published by American Chemical Society 2023 The Authors
Copyright_xml – notice: 2023 The Authors. Published by American Chemical Society
– notice: 2023 The Authors. Published by American Chemical Society 2023 The Authors
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1021/acsabm.3c00254
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 2576-6422
EndPage 2621
ExternalDocumentID PMC10354745
37368486
10_1021_acsabm_3c00254
b671260246
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: R01 DA052271
– fundername: NIDA NIH HHS
  grantid: R01 DA042706
– fundername: NIDA NIH HHS
  grantid: R01 DA034547
– fundername: NIDA NIH HHS
  grantid: R01 DA040537
– fundername: NIDA NIH HHS
  grantid: R01 DA037838
– fundername: ;
  grantid: DA040537
– fundername: ;
  grantid: DA037838
– fundername: ;
  grantid: 8AZ04
– fundername: ;
  grantid: DA042706
– fundername: ;
  grantid: DA034547
GroupedDBID 53G
ABFRP
ABQRX
ABUCX
ACS
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
EBS
GGK
VF5
VG9
AAYXX
ABBLG
ABJNI
ABLBI
BAANH
CITATION
CUPRZ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-a426t-45ab455ab558db20a58a1cd7ebf57b71e33511ccbb71bc8d5de94c4ee628dfa73
IEDL.DBID ACS
ISSN 2576-6422
IngestDate Thu Aug 21 18:36:40 EDT 2025
Thu Jul 10 20:09:58 EDT 2025
Thu Apr 03 07:09:53 EDT 2025
Tue Jul 01 04:25:48 EDT 2025
Thu Apr 24 23:12:27 EDT 2025
Wed Jul 19 06:54:57 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Nanotherapeutics
Nanomaterials
Nanotechnology
Neurological disorders
Immune interactions
Language English
License https://creativecommons.org/licenses/by-nc-nd/4.0
Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a426t-45ab455ab558db20a58a1cd7ebf57b71e33511ccbb71bc8d5de94c4ee628dfa73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-7519-1863
0000-0001-5574-673X
0000-0002-2843-1166
0000-0001-7441-0545
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC10354745
PMID 37368486
PQID 2830218808
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10354745
proquest_miscellaneous_2830218808
pubmed_primary_37368486
crossref_primary_10_1021_acsabm_3c00254
crossref_citationtrail_10_1021_acsabm_3c00254
acs_journals_10_1021_acsabm_3c00254
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-17
PublicationDateYYYYMMDD 2023-07-17
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-17
  day: 17
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle ACS applied bio materials
PublicationTitleAlternate ACS Appl. Bio Mater
PublicationYear 2023
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref45/cit45
ref3/cit3
ref27/cit27
ref56/cit56
ref16/cit16
Vashist A. (ref48/cit48) 2018
ref52/cit52
ref23/cit23
ref8/cit8
ref31/cit31
ref2/cit2
ref34/cit34
ref37/cit37
ref20/cit20
ref17/cit17
ref10/cit10
ref35/cit35
ref53/cit53
ref19/cit19
ref21/cit21
ref42/cit42
ref46/cit46
ref49/cit49
ref13/cit13
ref24/cit24
ref38/cit38
ref50/cit50
ref54/cit54
ref6/cit6
ref36/cit36
ref18/cit18
ref11/cit11
ref25/cit25
ref29/cit29
ref32/cit32
ref39/cit39
ref14/cit14
ref5/cit5
ref51/cit51
ref43/cit43
ref28/cit28
ref40/cit40
Cacabelos R. (ref4/cit4) 1991; 13
ref26/cit26
ref55/cit55
ref12/cit12
ref15/cit15
ref41/cit41
ref22/cit22
ref33/cit33
ref30/cit30
ref47/cit47
ref1/cit1
ref44/cit44
ref7/cit7
References_xml – ident: ref18/cit18
  doi: 10.1016/j.heliyon.2022.e09575
– ident: ref52/cit52
  doi: 10.1016/j.jconrel.2017.11.040
– ident: ref25/cit25
  doi: 10.1016/j.biomaterials.2016.05.044
– ident: ref38/cit38
  doi: 10.3390/cells8020154
– ident: ref26/cit26
  doi: 10.1126/sciadv.aay8514
– ident: ref33/cit33
  doi: 10.1016/j.biopha.2018.12.133
– ident: ref41/cit41
  doi: 10.3389/fimmu.2014.00658
– ident: ref24/cit24
  doi: 10.1021/acsami.2c13129
– ident: ref10/cit10
  doi: 10.1096/fj.09-141754
– ident: ref21/cit21
  doi: 10.1111/jphp.13132
– ident: ref31/cit31
  doi: 10.1021/acsanm.2c01930
– ident: ref53/cit53
  doi: 10.1002/jps.24557
– ident: ref20/cit20
  doi: 10.1039/C7NR07255D
– ident: ref51/cit51
  doi: 10.1016/j.biomaterials.2015.11.057
– ident: ref45/cit45
  doi: 10.1021/acs.bioconjchem.9b00085
– ident: ref16/cit16
  doi: 10.20517/evcna.2021.04
– ident: ref46/cit46
  doi: 10.1016/j.jconrel.2018.08.035
– ident: ref37/cit37
  doi: 10.3389/fimmu.2020.607945
– ident: ref28/cit28
  doi: 10.1016/j.mam.2021.101046
– ident: ref34/cit34
  doi: 10.1080/10717544.2021.1883158
– ident: ref23/cit23
  doi: 10.1002/btm2.10160
– ident: ref30/cit30
  doi: 10.1021/acs.chemrev.5b00589
– ident: ref6/cit6
  doi: 10.1016/0304-3940(91)90490-K
– ident: ref22/cit22
  doi: 10.1021/acs.molpharmaceut.2c00763
– start-page: 1
  volume-title: Nanogels for Biomedical Applications
  year: 2018
  ident: ref48/cit48
– ident: ref50/cit50
  doi: 10.3389/fbioe.2020.00315
– ident: ref1/cit1
  doi: 10.1016/S1474-4422(19)30029-8
– ident: ref54/cit54
  doi: 10.1208/s12249-014-0189-5
– ident: ref3/cit3
  doi: 10.1016/bs.pmbts.2019.10.002
– ident: ref19/cit19
  doi: 10.1016/j.brainres.2020.146738
– ident: ref43/cit43
  doi: 10.1126/science.aau6977
– ident: ref27/cit27
  doi: 10.1021/acs.biomac.0c01033
– ident: ref15/cit15
  doi: 10.1016/j.addr.2022.114636
– ident: ref8/cit8
  doi: 10.1038/nm.2965
– ident: ref40/cit40
  doi: 10.1186/1750-1326-8-2
– ident: ref56/cit56
  doi: 10.1007/s13365-023-01138-y
– ident: ref36/cit36
  doi: 10.2217/nnm-2018-0021
– ident: ref17/cit17
  doi: 10.1016/j.ijpharm.2022.122168
– ident: ref7/cit7
  doi: 10.1002/jnr.1097
– ident: ref49/cit49
  doi: 10.3389/fbioe.2022.954470
– ident: ref5/cit5
  doi: 10.1111/j.1365-2990.1995.tb01063.x
– ident: ref35/cit35
  doi: 10.1126/scirobotics.aaz9519
– ident: ref39/cit39
  doi: 10.1007/s12035-016-9851-0
– ident: ref47/cit47
  doi: 10.1021/acsnano.2c08774
– ident: ref44/cit44
  doi: 10.1021/acsbiomaterials.2c01329
– volume: 13
  start-page: 455
  issue: 7
  year: 1991
  ident: ref4/cit4
  publication-title: Methods and findings in experimental and clinical pharmacology
– ident: ref42/cit42
  doi: 10.7150/thno.62330
– ident: ref32/cit32
  doi: 10.1016/j.jconrel.2020.01.009
– ident: ref55/cit55
  doi: 10.1016/j.matdes.2022.110741
– ident: ref13/cit13
  doi: 10.1021/acsami.2c14220
– ident: ref29/cit29
  doi: 10.1186/s12951-022-01595-3
– ident: ref2/cit2
  doi: 10.1016/S1474-4422(19)30411-9
– ident: ref12/cit12
  doi: 10.1021/acs.molpharmaceut.0c00170
– ident: ref9/cit9
  doi: 10.3233/JAD-200056
– ident: ref14/cit14
  doi: 10.1002/advs.202003937
– ident: ref11/cit11
  doi: 10.1016/j.addr.2018.08.005
SSID ssj0002003189
Score 2.4267404
SecondaryResourceType review_article
Snippet Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side-...
Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side-...
SourceID pubmedcentral
proquest
pubmed
crossref
acs
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2614
SubjectTerms Drug Delivery Systems
Humans
Nanotechnology - methods
Neurodegenerative Diseases - drug therapy
Pharmaceutical Preparations
Review
Title Recent Advances in Nanotherapeutics for Neurological Disorders
URI http://dx.doi.org/10.1021/acsabm.3c00254
https://www.ncbi.nlm.nih.gov/pubmed/37368486
https://www.proquest.com/docview/2830218808
https://pubmed.ncbi.nlm.nih.gov/PMC10354745
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS8QwEA66XvTg-1FfVBQ8ZW3zaLMXYRGXRdCLLuytJGkWF7Urtnvx1ztJ23UfLHopgQ6hyUwyXzOZbxC6AggfqEBRbFoyxkxpim1CJw6kYlxypmhgE5wfn6Jujz30ef_3vGM-gk_CG6lzqT6aVLvE7VW0RiJYwRYE3T1PTlOIM06LdS2AxgCqSc3QuNCF9UM6n_VDC-By_o7klNPpbJUMSLnjKrR3Td6a40I19fcik-Of49lGmxXy9NulqeygFZPtoo0pPsI9dAsgEj7Eb5cXA3J_mPmw_U4naeU-oFzfUXpUu6ZfE3jm-6jXuX-56-KqwAKW4JgLDNoAjcCDc5EqEkguZKjT2KgBj1UcGmrDjForaCstUp6aFtPMmIiIdCBjeoAa2SgzR8iHHzHVCkkU29q_JIQutdA6ojRSAzqg2kOXMPCkWiB54mLfJEzK2Uiq2fAQrpWS6Iqj3JbKeF8qfz2R_yzZOZZKXtQ6TmAB2aiIzMxonCeOAc2y0gkPHZY6n_RFYxoJJiIPiRlrmAhYcu7ZN9nw1ZF0hwHlLGb8-F8DP0Hrto49doydp6hRfI3NGaCdQp07Q_8BW1r6pw
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEB58HNSD78f6rCh4ym7bJG32IiyirE8EFbyVJM2iqFXs7sVf7yR9uKsIeimlHYYkM8l8bTLfAOwjhPeVrygxbRkTpjQlNqGT-FIxLjlT1LcJzpdXUfeOnd3z-zFoVbkw2IgcNeVuE_-LXSBo4TOpXppUu_ztcZhEJBJal-4c3dQ_VULnoxbyWhxNEFuHFVHjDxU2HOl8NBz9wJjfj0oOxZ6TObiuW-2OnDw1B33V1B_fCB3_0a15mC1xqNcpHGcBxky2CDND7IRLcIiQEtvjdYpjArn3mHm4GA-nbOUeYl7PEXyUa6hX0Xnmy3B3cnx71CVluQUiMUz3CdoG7YMXzkWqQl9yIQOdxkb1eKziwFC76ai1wnulRcpT02aaGROFIu3JmK7ARPaamTXw8LNMtYMwim0l4DBAlVpoHVEaqR7tUd2APex4Uk6XPHE74WGQFKORlKPRAFLZJtElY7ktnPH8q_xBLf9WcHX8KrlbmTrB6WT3SGRmXgd54vjQLEedaMBqYfpaF41pJJiIGiBGnKIWsFTdo2-yxwdH2R34lLOY8fU_dXwHprq3lxfJxenV-QZM2wr3xHF5bsJE_31gthAH9dW28_1PqG0DFw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEB58gOjB92N9VhQ8ZW2bpM1ehEVdfCOo4K0kaYqLWsXuXvz1TtJu2VUEvZTSDkOSmSRfO5lvAPYRwvvKV5SYlowJU5oSm9BJfKkYl5wp6tsE5-ub6OyBXTzyxyqP2-bCYCMK1FS4IL6d1e9pVjEMBIf4XKrXJtUuh3scJm3Mzrp1-_iu_rESOj-1sNdiaYL4OhyQNf5QYbckXYxuST9w5vfjkkP7T2cO7uuWu2Mnz81-TzX15zdSx392bR5mKzzqtUsHWoAxky_CzBBL4RIcIbTENnnt8rhA4XVzDxfl4dStwkPs6zmij2ot9Qa0nsUyPHRO74_PSFV2gUjcrnsEbYR2wgvnIlWhL7mQgU5jozIeqzgw1AYftVZ4r7RIeWpaTDNjolCkmYzpCkzkb7lZAw8_z1QrCKPYVgQOA1SphdYRpZHKaEZ1A_aw40k1bYrERcTDIClHI6lGowFkYJ9EV8zltoDGy6_yB7X8e8nZ8avk7sDcCU4rGyuRuXnrF4njRbNcdaIBq6X5a100ppFgImqAGHGMWsBSdo--ybtPjro78ClnMePrf-r4DkzdnnSSq_Obyw2YtoXuiaP03ISJ3kffbCEc6qlt5_5fAu4Fmg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+Advances+in+Nanotherapeutics+for+Neurological+Disorders&rft.jtitle=ACS+applied+bio+materials&rft.au=Vashist%2C+Arti&rft.au=Manickam%2C+Pandiaraj&rft.au=Raymond%2C+Andrea+D.&rft.au=Arias%2C+Adriana+Yndart&rft.date=2023-07-17&rft.issn=2576-6422&rft.eissn=2576-6422&rft.volume=6&rft.issue=7&rft.spage=2614&rft.epage=2621&rft_id=info:doi/10.1021%2Facsabm.3c00254&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acsabm_3c00254
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2576-6422&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2576-6422&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2576-6422&client=summon